Biotech | November 18, 2021
AstraZeneca’s Covid-19 drug offers 83% protection over six months
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021
Evidence also shows better immune response to virus among users of spray
The new facility will provide an important boost to vaccine capacity in Africa
It is the world’s first DNA-based Covid vaccine
The preregistrations are aimed at registering both healthy children and those with comorbidities whereas preference will be given for children with comorbidities
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
